ASGCT Annual Meeting: Celebrating 25 Years in 2022
The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting, celebrating its 25th year in 2022, is the premier event for professionals in gene and cell therapy. The four-day meeting—and one preceding day of Pre-Meeting Workshops—is the best place for people in the field to learn from the latest scientific research, stay up to date on new technologies, and make career-advancing connections with peers.
Originally designed as a venue for academic researchers to share their work, the Annual Meeting has grown to serve a wide community encompassing clinicians, bio-industry development, regulatory agencies, equipment manufacturers, patient advocates, and more.
Register for virtual or in-person program here: https://annualmeeting.asgct.org/register.
ASGCT Annual Meeting 2022 NEWS
How to address challenges in producing AAV vectors
May 23, 2022 -- There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors, contends Ines do Carmo Gil-Goncalves, PhD, head of vector production for Cevec Pharmaceuticals GmbH. Gil-Goncalves discussed how Cevec’s Elevecta platform can help overcome these challenges at the American Society of Gene & Cell Therapy 2022 annual meeting.
May 23, 2022 -- There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors, contends Ines do Carmo Gil-Goncalves, PhD, head of vector production for Cevec Pharmaceuticals GmbH. Gil-Goncalves discussed how Cevec’s Elevecta platform can help overcome these challenges at the American Society of Gene & Cell Therapy 2022 annual meeting.
ASGCT 2022 shows how far cell and gene therapy has come, needs to go
May 20, 2022 -- The American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting was held this week in Washington, DC, demonstrating how far the field has come in the last quarter of a century. ASGCT 2022's scientific, educational, and plenary sessions all drove home the potential of new cell and gene therapy treatments for a wide array of diseases.
May 20, 2022 -- The American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting was held this week in Washington, DC, demonstrating how far the field has come in the last quarter of a century. ASGCT 2022's scientific, educational, and plenary sessions all drove home the potential of new cell and gene therapy treatments for a wide array of diseases.
Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
May 20, 2022 -- Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation, according to Thomas McCauley, PhD, chief scientific officer. McCauley spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy annual meeting in Washington, DC.
May 20, 2022 -- Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation, according to Thomas McCauley, PhD, chief scientific officer. McCauley spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy annual meeting in Washington, DC.
Delivery of gene therapies remains a key challenge
May 19, 2022 -- Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge, contends Kevin Foust, PhD, senior vice president for preclinical and translational medicine at Jaguar Gene Therapy. Foust spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy annual meeting in Washington, DC.
May 19, 2022 -- Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge, contends Kevin Foust, PhD, senior vice president for preclinical and translational medicine at Jaguar Gene Therapy. Foust spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy annual meeting in Washington, DC.
Next evolution of CAR T-cell therapy is solid tumors
May 18, 2022 -- While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the technology is solid tumors, said Sangamo CEO Sandy Macrae, PhD, at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC.
May 18, 2022 -- While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the technology is solid tumors, said Sangamo CEO Sandy Macrae, PhD, at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC.